Introduction
1 mucosal adjuvants like, LT192G, the non-toxic mutant form 23 of Escherishia coli heat-labile enterotoxin (LT), or containing oligodeoxynucleotides [9] . However, intranasal 25 immunization has emerged as the optimal vaccination strat-26 egy in rodents for induction of antibody responses in genital 27 tissues [10] [11] [12] and was also shown to be effective in human 28 studies [11, 13, 14] . Intranasal immunization of mice with 29 HPV16 L1 protein or the HPV16 L1 gene in combination 30 with the adjuvant cholera toxin was shown to elicit sys-31 temic and mucosal humoral and cellular immune responses 32 [15] . Recently, it was reported that intranasal immunization ter. They were maintained in DMEM supplemented with 10% 87 heat-inactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 88 100 g streptomycin and 400 g/ml G418. 
Peptides

90
The E7 44-62 peptide, Q19D (QAEPDRAHVYNIVTFC-91 CKCD) and the E6 43-57 peptide, Q15L (QLLRREVYD-92 FAFRDL) were used for immunization of mice. In addition 93 to these peptides, the E7 49-57 peptide, R9F (RAHVYNIVTF) 94 and the E6 49-58 peptide, V10C (VYDFAFRDLC) that repre-95 sent murine H2 b -restricted CTL epitopes, were used in the 96 CTL assays. All the peptides were prepared in the insti-97 tutional antigen-core facility utilizing FMOC solid phase 98 chemistry on a PTI Symphony Peptide Synthesizer (Pro-99 tein Technologies Inc., Tucson, Arizona). Peptide purity was 100 determined to be >95% by high-pressure liquid chromatog-101 raphy (HPLC) and was validated by mass spectrometry. 
Mutant cholera toxin (CT-2 * )
103
The CT-2 * protein, a mutant form of the cholera toxin, 104 produced by a vaccine strain of V. cholerae, was purified 105 to homogeneity by sodium hexametaphosphate precipitation, 106 affinity purification on a galactose column and Sephadex G75 107 gel filtration chromatography as described earlier [25] [26] [27] [28] . 108 The purified toxin was dissolved in pyrogen-free water, 109 and the lipopolysaccharide (LPS) contamination was deter-110 mined by the Limulus amebocyte lysate assay (QCL-1000kit, 111 BioWhitaker, Walkerville, MD). The amount of LPS detected 112 in 1 g of CT-2 * (amount used as adjuvant in mice) was 113 0.5 pg, which did not stimulate production of any cytokine in 114 the mouse ligated ileal loops [25] [26] [27] [28] . The CTL assay was carried out as described previously epitopes within the Q19D and Q15L sequences, respectively. 227 Furthermore, significant lysis of the TC-1 tumor cells that 228 express the E7 and E6 oncoproteins of HPV-16 was also 229 observed by the spleen and CLN cells from these immu-230 nized mice. The specific lysis values at an E:T ratio of 100:1 231 were 38% and 20% for the spleen and the CLN cells, respec-232 tively (Fig. 1) . The values were compared to those obtained 233 with EG7·Ova targets and were found to be highly signifi-234 cant (p ≤ 0.00005). No CTL activity was observed both in the 235 spleen and CLN against either the Yac-1 cells (NK targets) or 236 the EG7·Ova cells (syngeneic tumor cells expressing the non-237 specific ovalbumin antigen) used as targets (Fig. 1) indicating 238 the antigen-specificity of the CTL responses induced. 
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Immunization with the mixture of the Q19D and
240
Q15L peptides induces IFN-γ production by CD4 + and
241
CD8 + T cells from the systemic and mucosal
242 compartments 243 We also determined whether the mucosal immunization 244 protocol adopted was effective in priming antigen-specific 245 cellular immune responses in different mucosal and sys-246 temic compartments. For this, cells isolated from different 247 tissues of mice immunized with the mixture of Q19D and 248 Q15L peptides along with the CT-2 * adjuvant were assayed 249 for antigen-specific IFN-␥ production by CD8 + and CD4 + 250 T cells. As shown in Fig. 2A we observed significant per-251 centages of CD8 + T cells producing IFN-␥ in response to 252 stimulation with the Q19D peptide in the spleen (7.88%), 253 the draining cervical lymph nodes (4.58%), as well as mul-254 tiple mucosal tissues like the MLN (6.26%), Peyer's patches 255 (9.41%), and the VALT (14.5%). Similar responses were 256 observed in the cells from the various tissues in response to 257 stimulation with the Q15L peptide (7.92% in spleen, 5.95% 258 in CLN, 5.96% in MLN, 11.7% in PP, and 11.3% in VALT). 259 We also observed strong IFN-␥ production by CD4 + T cells in 260 response to both Q19D and Q15L (Fig. 2B) . No positive CD8 261 and CD4 responses were observed for all the tissues with the 262 negative control peptide used for stimulation ( Fig. 2A and B) . 263 Overall, the amounts of IFN-␥ producing CD8 + T cells were 264 comparable to that of CD4 + T cells in response to Q19D as 265 well as Q15L peptides (Fig. 2C) .
266
We also measured the number of antigen-specific IFN-␥ 267 producing cells generated by intranasal immunization with 268 the HPV peptides and CT-2 * on the day of sacrifice by 269 ELISPOT assay. (Fig. 3A) , CLN and MLN (Fig. 3B) . for tumor development over 15 days. As shown in Fig. 4A 
Discussion
328
Both the E7 and E6 oncoproteins of HPV are expressed in 329 pre-neoplastic as well as cancerous lesions of the cervix and 330 represent potential targets for prophylaxis and immunother-331 apy approaches. Most studies to date focused on the 332 development of vaccines employing either the whole E7 or E6 333 proteins in separate formulations or individual immunogenic 334 peptides corresponding to these proteins [30] [31] [32] [33] . Peptide-335 based vaccines have gained much importance over the last 336 Fig. 3 . Induction of peptide specific IFN-␥ producing cells by intranasal immunization with the mixture of E7 44-62 (Q19D) and E6 43-57 (Q15L) peptides from HPV-16 using the mutant cholera toxin (CT-2 * ) as adjuvant. Cells isolated from spleen, CLN and MLN of C57BL/6 mice immunized by the intranasal route with mixture of Q19D and Q15L peptides were stimulated in vitro using medium, cognate peptides or a non-specific negative control peptide individually (2 g/ml) in a 96 well plate ELISPOT. After 48 h the plates were washed and developed and the number IFN-␥ producing spot forming cells were enumerated in each well and the number of spot forming cells calculated per 1 × 10 6 cells is plotted. Average values and errors bars were calculated from two separate experiments consisting of three mice in each. Responses were considered positive when they were above 50 SFC/well and at least double the number obtained in cells cultured with medium alone (this cut-off value shown as horizontal line in the two panels). The p-values were calculated comparing with the medium alone control and values ≤0.05 (*) are considered significant. decade as they are relatively easy to construct and pro-337 duce, chemically stable, and unlike the E6 and E7 proteins, vaccines [8, 34, 35] .
343
In a previous study [36] , we demonstrated the immuno- [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] (Q19D) and E6 43-57 (Q15L) peptides from HPV-16 using the mutant cholera toxin (CT-2 * ) adjuvant protects mice against challenge with the TC-1 tumor cells. Three experimental groups of C57BL/6 mice were included: naïve unimmunized mice were injected subcutaneously on the right flank with 1 × 10 5 TC-1 tumor cells per mouse (group 1, n = 6); mice immunized intranasally with the mixture of Q19D and Q15L peptides (100 g each) along with CT-2 * adjuvant (1 g) twice at 5 days intervals and 1 week after the last immunization injected subcutaneously on the right flank with either 1 × 10 6 EG7·Ova tumor cells per mouse (group 2, n = 6) or 2 × 10 5 TC-1 tumor cells per mouse (group 3, n = 10). The size of the tumors (length + width/2) on days 7 and 15 was measured in all three groups were measured and the average values plotted (panel A). Panel B shows the percentages of mice tumor-free over a period of 60 days follow-up in the three different groups: Data for group 1 is shown as light gray line, as dark gray line for group 2, and as black line for group 3. Statistical analysis between the three groups was done using the Student's t-test.
an E7-derived Th epitope, potentiated antigen specific CTL 351 responses in mice [32] . The Q15L peptide from the E6 onco-352 protein used in our study overlaps with a murine CTL epitope 353 peptide (E6 48-57 , presented by H-2K b ) reported by Peng 354 et al. [37] . Results from the present investigation demon-355 strated that intranasal immunization with a mixture of the E7 356 and E6 peptides, Q19D and Q15L, using the mucosal adju-357 vant CT-2 * , induced strong antigen-specific T cell responses 358 that afforded protection against challenge with tumor cells 359 expressing the E6 and E7 oncoproteins of HPV-16. Impor-360 tantly, antigen-specific T cell responses, in terms of IFN-␥ 361 producing CD4 + and CD8 + T cells in response to the pep-362 tides used for immunization of mice were observed in the 363 VALT. No positive peptide specific antibody responses (IgG 364 and IgA) were observed in the serum, saliva and vaginal 365 washes (data not shown) tested at different time points by 366
